1. Home
  2. BDSX vs CRBP Comparison

BDSX vs CRBP Comparison

Compare BDSX & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BDSX
  • CRBP
  • Stock Information
  • Founded
  • BDSX 2005
  • CRBP 2009
  • Country
  • BDSX United States
  • CRBP United States
  • Employees
  • BDSX N/A
  • CRBP N/A
  • Industry
  • BDSX Precision Instruments
  • CRBP Biotechnology: Pharmaceutical Preparations
  • Sector
  • BDSX Health Care
  • CRBP Health Care
  • Exchange
  • BDSX Nasdaq
  • CRBP Nasdaq
  • Market Cap
  • BDSX 245.3M
  • CRBP 227.3M
  • IPO Year
  • BDSX 2020
  • CRBP N/A
  • Fundamental
  • Price
  • BDSX $1.60
  • CRBP $17.67
  • Analyst Decision
  • BDSX Strong Buy
  • CRBP Strong Buy
  • Analyst Count
  • BDSX 4
  • CRBP 7
  • Target Price
  • BDSX $3.08
  • CRBP $65.86
  • AVG Volume (30 Days)
  • BDSX 118.2K
  • CRBP 716.7K
  • Earning Date
  • BDSX 11-01-2024
  • CRBP 11-05-2024
  • Dividend Yield
  • BDSX N/A
  • CRBP N/A
  • EPS Growth
  • BDSX N/A
  • CRBP N/A
  • EPS
  • BDSX N/A
  • CRBP N/A
  • Revenue
  • BDSX $60,902,000.00
  • CRBP N/A
  • Revenue This Year
  • BDSX $48.06
  • CRBP N/A
  • Revenue Next Year
  • BDSX $29.97
  • CRBP N/A
  • P/E Ratio
  • BDSX N/A
  • CRBP N/A
  • Revenue Growth
  • BDSX 46.25
  • CRBP N/A
  • 52 Week Low
  • BDSX $1.15
  • CRBP $3.03
  • 52 Week High
  • BDSX $2.21
  • CRBP $61.90
  • Technical
  • Relative Strength Index (RSI)
  • BDSX 39.90
  • CRBP 27.02
  • Support Level
  • BDSX $1.59
  • CRBP $18.20
  • Resistance Level
  • BDSX $1.68
  • CRBP $19.72
  • Average True Range (ATR)
  • BDSX 0.06
  • CRBP 1.07
  • MACD
  • BDSX -0.01
  • CRBP 1.12
  • Stochastic Oscillator
  • BDSX 20.51
  • CRBP 11.01

About BDSX Biodesix Inc.

Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: